Stay updated on Nivolumab Ibrutinib in CLL Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Ibrutinib in CLL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Ibrutinib in CLL Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The study page now displays the clinical-trial record, including its treatment plan, eligibility criteria, outcomes, completion status, and study documents.
    Difference
    63%
    Check dated 2026-11-08T23:14:59.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T23:15:06.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces updates and FAQs about replacing “Artificial Intelligence” with “Super Intelligence” in federal agency content. The clinical trial record remains unavailable behind a 403 error.
    Difference
    1%
    Check dated 2026-10-25T22:37:22.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The footer revision number changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T22:45:07.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision label changes from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T23:06:34.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    A 403 Forbidden message appears in place of the clinical study record, with a Home link.
    Difference
    0.5%
    Check dated 2026-10-04T22:29:31.000Z thumbnail image

Stay in the know with updates to Nivolumab Ibrutinib in CLL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Ibrutinib in CLL Clinical Trial page.